Cell-free DNA screening performance table
Performance of cell-free DNA screening by condition
Note that each laboratory may have different conditions offered for cfDNA screening and their own lab-specific analytic data.
False positive rate
Positive predictive value1
|High risk2||General population|
|Sex chromosome conditions3||90-93%||>99%||<1%||25-52%||25-41%|
1Positive predictive values (PPV) presented are estimates for educational purposes. PPV will be specific to a given patient based on age and other characteristics. See the NIPT PPV calculator to see personalized risk estimates for a given patient.
2High risk = advanced maternal age, personal/family history, positive other screening, ultrasound abnormality
3Includes XO (Monosomy X, Turner syndrome), XXY (Klinefelter syndrome), Trisomy X (Triple X syndrome), and XYY (Jacob syndrome). Limited validity data available.
4Includes 22q11.2 deletion syndrome (DiGeorge syndrome), 1p36 deletion syndrome, 15q11.2 deletion (Angelman and Prader-Willi syndromes), 5p deletion (Cri-du-chat syndrome), and 4p deletion (Wolf-Hirschhorn syndrome). Limited validity data available.
ACOG and SMFM, Practice bulletin #163: Screening for fetal aneuploidy. 2016.
ACOG and SMFM, Committee Opinion #640: Cell-Free DNA Screening For Fetal Aneuploidy. Obstet Gynecol, 2015; 126(3):e31-7.
Gil, M.M., et al., Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol, 2015; 45(3):249-66.
Gregg, A.R., et al., Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med, 2016.
Taylor-Phillips, S., et al., Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open, 2016; 6(1): p. e010002.